Sirin Kose Seda, Atakul Gizem, Asilsoy Suna, Karaman Ozkan, Uzuner Nevin, Anal Ozden
Division of Pediatric Immunology and Allergy, Dokuz Eylul University, Izmir, Turkey.
Eur Arch Otorhinolaryngol. 2019 Mar;276(3):729-734. doi: 10.1007/s00405-018-5251-6. Epub 2018 Dec 15.
Allergic rhinitis (AR) is a very common, chronic and global health problem. In the last two decades, the efficiency of barrier-enforcing measures in AR has been investigated. In this study, we aimed to evaluate the effect of allergen-blocker mechanical barrier gel (MBG) (AlerjiSTOP) treatment on symptoms and quality of life score (QoLS) in patients with seasonal and perennial allergic rhinitis.
A single-center, prospective study was conducted between January 2017 and May 2018. Patients diagnosed with allergic rhinitis with a visual analogue scale (VAS) of 5 or higher (moderate/severe) were enrolled in the study. Patients were evaluated in terms of VAS, nasal symptom score (NSS), ocular symptom score (OSS), total symptom score (TSS) and QoLS at baseline, 1 week and 1 month of MBG treatment.
A total of 83 patients with AR were enrolled in the study. Clinical and laboratory examinations showed that 50 (60.2%) patients were mono-sensitized. Allergen-blocker mechanical barrier gel treatment was performed as monotherapy in 22 (26.5%) patients. Median VAS, NSS, OSS and TSS decreased from 7 to 4, 8 to 3, 4 to 0 and 12 to 4, respectively (p < 0.0001). Correlation analysis revealed positive correlations between lower pediatric rhinoconjunctivitis quality of life questionnaire scores for patients under 12 years of age and decrease in VAS, NSS and TSS (r = 0.380, p = 0.008; r = 0.544, p < 0.0001; r = 0.543, p < 0.0001). Positive correlations were detected between lower rhinoconjunctivitis quality of life questionnaire (self-administered) scores for patients ≥ 12 years of age and decrease in VAS, NSS, OSS and TSS (r = 0.703, p < 0.0001; r = 0.465, p = 0.005; r = 0.526, p = 0.001; r = 0.624, p < 0.0001).
In conclusion, we found significant decrease in all symptom scores and improvement in QoLS of patients treated with MBG as monotherapy and combination therapy.
变应性鼻炎（AR）是一种非常常见的慢性全球性健康问题。在过去二十年中，已对变应性鼻炎中强化屏障措施的效果进行了研究。在本研究中，我们旨在评估变应原阻断机械屏障凝胶（MBG）（AlerjiSTOP）治疗对季节性和常年性变应性鼻炎患者症状及生活质量评分（QoLS）的影响。
于2017年1月至2018年5月进行了一项单中心前瞻性研究。纳入视觉模拟量表（VAS）评分为5分或更高（中度/重度）的变应性鼻炎确诊患者。在MBG治疗的基线、1周和1个月时，根据VAS、鼻症状评分（NSS）、眼症状评分（OSS）、总症状评分（TSS）和QoLS对患者进行评估。
共有83例AR患者纳入本研究。临床和实验室检查显示，50例（60.2%）患者为单敏。22例（26.5%）患者将变应原阻断机械屏障凝胶治疗作为单一疗法。VAS、NSS、OSS和TSS的中位数分别从7降至4、8降至3、4降至0和12降至4（p＜0.0001）。相关性分析显示，12岁以下患者较低的儿童鼻结膜炎生活质量问卷评分与VAS、NSS和TSS降低之间存在正相关（r = 0.380，p = 0.008；r = 0.544，p＜0.0001；r = 0.543，p＜0.0001）。在≥12岁患者中较低的鼻结膜炎生活质量问卷（自行填写）评分与VAS、NSS、OSS和TSS降低之间检测到正相关（r = 0.703，p＜0.0001；r = 0.465，p = 0.005；r = 0.526，p = 0.001；r = 0.624，p＜0.0001）。
总之，我们发现接受MBG单一疗法和联合疗法治疗的患者所有症状评分均显著降低，QoLS有所改善。
